| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/TAN.12614 |
| P698 | PubMed publication ID | 26206374 |
| P2093 | author name string | D Charron | |
| R Al-Daccak | |||
| P2860 | cites work | Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives | Q26849530 |
| Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease | Q26865070 | ||
| Effector mechanisms of rejection | Q27027082 | ||
| Immunogenicity of induced pluripotent stem cells | Q29616185 | ||
| Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial | Q29620043 | ||
| RETRACTED: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial | Q29620044 | ||
| Adult cardiac stem cells are multipotent and support myocardial regeneration | Q29620122 | ||
| The immunomodulatory capacity of mesenchymal stem cells | Q30318253 | ||
| Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction | Q30570123 | ||
| Non-self recognition by monocytes initiates allograft rejection | Q30584875 | ||
| A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. | Q33755344 | ||
| How stem cells speak with host immune cells in inflammatory brain diseases | Q33776557 | ||
| Natural immunity to pluripotency antigen OCT4 in humans | Q33928635 | ||
| Characterization of the expression of MHC proteins in human embryonic stem cells | Q34076010 | ||
| The generation and maintenance of serum alloantibody. | Q34106158 | ||
| Empowering adult stem cells for myocardial regeneration | Q34239856 | ||
| HLA DNA typing and transplantation | Q34241099 | ||
| Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? | Q34803754 | ||
| Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. | Q35050037 | ||
| Cardiac cell therapy: where we've been, where we are, and where we should be headed | Q35144550 | ||
| The link between major histocompatibility complex antibodies and cell proliferation | Q35223952 | ||
| MHC class II signaling in antigen-presenting cells | Q35634046 | ||
| Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells | Q35666637 | ||
| Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells | Q35799278 | ||
| Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response | Q35843862 | ||
| Humoral theory of transplantation: further evidence | Q36228533 | ||
| A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction | Q36634299 | ||
| Immunogenicity of allogeneic mesenchymal stem cells. | Q37294916 | ||
| Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways | Q37596125 | ||
| Immunogenicity and allogenicity: a challenge of stem cell therapy | Q37766166 | ||
| Mesenchymal Stem Cell Therapy for Cardiac Repair | Q37777383 | ||
| Anti-HLA antibodies in regenerative medicine stem cell therapy | Q38025802 | ||
| Antibody-mediated vascular rejection of kidney allografts: a population-based study | Q38062614 | ||
| Innate allorecognition. | Q38187174 | ||
| A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles | Q38236850 | ||
| Stem cells in the management of advanced heart failure | Q38287002 | ||
| The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease | Q38364658 | ||
| The role of human leukocyte antigen matching in the development of multiethnic "haplobank" of induced pluripotent stem cell lines | Q39449356 | ||
| Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. | Q40395995 | ||
| They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. | Q40409278 | ||
| Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells | Q42914079 | ||
| Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation | Q43208941 | ||
| What is the definition of a clinically relevant donor HLA-specific antibody (DSA)? | Q45241825 | ||
| Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains | Q46052807 | ||
| Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells | Q47787334 | ||
| Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction | Q48752975 | ||
| Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. | Q51058705 | ||
| An innate response to allogeneic nonself mediated by monocytes. | Q51888948 | ||
| HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. | Q52019798 | ||
| Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence. | Q53154015 | ||
| Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. | Q54465293 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 155-162 | |
| P577 | publication date | 2015-07-23 | |
| P1433 | published in | Tissue Antigens | Q1573131 |
| P1476 | title | Allogenic benefit in stem cell therapy: cardiac repair and regeneration | |
| P478 | volume | 86 |
| Q91442462 | A mechanistic roadmap for the clinical application of cardiac cell therapies |
| Q38676947 | Allogeneic cardiosphere-derived cells for myocardial regeneration: current progress and recent results |
| Q50025724 | An allogeneic 'off the shelf' therapeutic strategy for peripheral nerve tissue engineering using clinical grade human neural stem cells |
| Q61813274 | Editorial: Alloimmune Response From Regenerative Medicine |
| Q92511363 | Enhanced Immunomodulation in Inflammatory Environments Favors Human Cardiac Mesenchymal Stromal-Like Cells for Allogeneic Cell Therapies |
| Q92693967 | Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit |
| Q47144816 | Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair |
| Q37557961 | Immune responses to bioengineered organs. |
| Q45967826 | Neural Growth Factor Stimulates Proliferation of Spinal Cord Derived-Neural Precursor/Stem Cells. |
| Q26765883 | Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide? |
| Q92989010 | Therapeutic Cell Protective Role of Histochrome under Oxidative Stress in Human Cardiac Progenitor Cells |
Search more.